You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

    SBC: NEURODON, LLC            Topic: NIA

    In this Phase IIB SBIR project for Alzheimer’s disease (AD) drug development, Neurodon LLC proposes to conduct preclinical development and IND-enabling activities on our novel, orally available lead and backup compounds that, in our preceding Phase II project, showed neuroprotection and beneficial effects on learning and memory in a transgenic model of AD. Despite the enormity of AD as a nationa ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Point-of-care lateral flow immunoassay for diagnosis of pertussis

    SBC: DXDISCOVERY INC            Topic: NIAID

    Pertussis (Whooping cough) is a highly contagious, airborne disease that is rapidly re-emerging as a serious public health threat in the United States. Despite high vaccine coverage, annual reported cases in the U.S. have been increasing recently, with an average of 25,000 per year from 2010-2019. This is a level unseen since the early 1960s. Diagnosis of pertussis is challenging because its early ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: 100

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. All-in-one Device for Forensic Toxicology Drug Screening

    SBC: WIK DEVICES LLC            Topic: NIDA

    Project Summary/AbstractDrug screening in toxicology cases is performed mainly using immunoassays, gas- chromatography mass spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-MS). Immunoassays lack the sensitivity, multiplexing capability, and flexibility to respond to the rise of potent synthetic drugs including fentanyl analogs and synthetic cannabinoids. GC- MS requires exten ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Coccidioides Cytokine Release Assay

    SBC: MIRAVISTA DIAGNOSTICS LLC            Topic: NIAID

    Coccidioidomycosis (CM) is an endemic mycosis caused by the fungi Coccidioides immitis and Coccidioides posadasii, which is native to arid regions of North and South America. It is estimated that up to 350,000 infections occur annually in the U.S. Additionally, up to a third of community acquired pneumonia cases in these areas are thought to be a result of CM. Morbidity associated with CM is subst ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Fluoroscopic drill attachment for orthopedic trauma surgery

    SBC: ECLIPSE ORTHOPAEDICS, LLC            Topic: NIAMS

    Abstract For about 175,000 leg and hip fractures each year, the best treatment is for an orthopaedic surgeon to implant a stiff metal rod, or intramedullary (IM) nail, through the center of the bone and fix the nail to the bone with screws (distal locking). Distal locking can be difficult and time-consuming step and presents two major challenges. First, the procedure uses C-arm fluoroscopy for gui ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer

    SBC: Kovina Therapeutics Inc.            Topic: NCI

    ABSTRACT “High-risk” human papillomavirus (HPV) types such as 16 (HPV-16) are identified in the majority of HPV-associated pre-malignant and malignant pathologies of cervical, anogenital, and oropharyngeal epithelia. TheE6 protein is essential for viral replication. Structure-based computational screening followed by design andsynthesis of derivatives led to the identification of a series of s ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Augmented Reality Platform for Feedback and Assessment in STEM Elementary Education

    SBC: EXPLORE INTERACTIVE, INC            Topic: 500

    Delivering meaningful, project-based learning for science and engineering in elementary classrooms is increasingly recognized as essential for training the workforce required to solve our most pressing health and environmental problems. However, many educators and classrooms are not adequately supported with the funding, materials, or training necessary to conduct and assess effective learning act ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Renal Therapeutic Angiogenesis Using the Novel Biologic ELP-VEGF

    SBC: LEFLORE TECHNOLOGIES LLC            Topic: 400

    Abstract.Chronic kidney disease (CKD) is a progressive disorder affecting almost 14% of the general population, and this disease has shown a relentless growth over the past 2 decades. Patients with CKD have higher rates of hospitalization, greater mortality, shorter life expectancy, and their healthcare costs are up to 5 times more expensive than non-CKD patients. Thus, treatments to slow, halt, o ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government